Advertisement
UK markets close in 5 hours 44 minutes

  • FTSE 100

    8,113.04
    +34.18 (+0.42%)
     

  • FTSE 250

    19,833.63
    +231.65 (+1.18%)
     

  • AIM

    755.73
    +2.61 (+0.35%)
     

  • GBP/EUR

    1.1656
    -0.0000 (-0.00%)
     

  • GBP/USD

    1.2515
    +0.0004 (+0.03%)
     

  • Bitcoin GBP

    51,528.75
    +445.41 (+0.87%)
     

  • CMC Crypto 200

    1,392.27
    -4.27 (-0.31%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    83.91
    +0.34 (+0.41%)
     

  • GOLD FUTURES

    2,361.60
    +19.10 (+0.82%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,041.51
    +124.23 (+0.69%)
     

  • CAC 40

    8,028.41
    +11.76 (+0.15%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Outlook on the Typhoid Fever Vaccines Global Market to 2027 - by Vaccine Type, Route of Administration and Country

Research and Markets
·7-min read

Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "North America Typhoid Fever Vaccines Market Forecast to 2027 - Covid-19 Impact and Regional Analysis by Vaccine Type and Route of administration and Country" report has been added to ResearchAndMarkets.com's offering.

According to this report the North America Neuromodulation market was valued at US$ 3,029.72 million in 2019 and is projected to reach US$ 6,612.00 million by 2027; it is expected to grow at a CAGR of 10.6% during 2020-2027. The report highlights the trends prevailing in the North America neuromodulation market and the factors driving the market along with those that act as deterrents to its growth.

Based on technology, the neuromodulation market is segmented external (non-invasive) neuromodulation and internal neuromodulation. In 2019, the internal neuromodulation segment accounted for the largest share of the North America neuromodulation market. The growth of the segment attributes to growth of internal neuromodulation segment is attributed to increasing product launches in the market, the rising product innovation for neuromodulation devices and growing developments in neuromodulation technology are some of the primary factors contributing to the dominance of the segment in the North America Neuromodulation market. Additionally, the outbreak of the COVID-19 pandemic has highly affected the countries in the North American region.

Abbott, Boston Scientific Corporation, Medtronic, NeuroPace, Inc., NeuroSigma, Inc., NEVRO CORP, Synapse Biomedical Inc., Soterix Medical Inc, Integer Holdings Corporation, and Magstim. are among the prominent players present in the neuromodulation market. The market players are focused on mergers and acquisitions to sustain their position in the market. For instance, in September 2020Boston Scientific announced the European launch of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs), offers expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain.

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America typhoid fever vaccines market.

  • Highlights key business priorities in order to assist companies to realign their business strategies.

  • The key findings and recommendations highlight crucial progressive industry trends in the North America typhoid fever vaccines market, thereby allowing players across the value chain to develop effective long-term strategies.

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

  • Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Typhoid Fever Vaccines Market - by Vaccine Type
1.3.2 North America Typhoid Fever Vaccines Market - by Route of Administration
1.3.3 North America Typhoid Fever Vaccines Market - by Country

2. North America Typhoid Fever Vaccines Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Typhoid Fever Vaccines Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America Typhoid Fever Vaccines Market - North America PEST Analysis
4.3 Expert Opinion

5. North America Typhoid Fever Vaccines Market Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Increase in Number of Americans Travelling Outside North America
5.2 Key Restraints
5.2.1 Risks Associated with Typhoid Fever Vaccines
5.3 Key Market Opportunities
5.3.1 Increasing Pharmaceutical and Biopharmaceutical Industry
5.4 Future Trend
5.4.1 Initiatives to Reduce Typhoid Burden
5.5 Impact Analysis

6. Typhoid Fever Vaccines Market - North America Analysis
6.1 North America Typhoid Fever Vaccines Market Revenue Forecasts and Analysis

7. Typhoid Fever Vaccines Market - by Vaccine Type
7.1 Overview
7.2 Typhoid Fever Vaccines Market, by Vaccine Type, 2019 and 2027 (%)
7.3 Live Attenuated Vaccine
7.3.1 Overview
7.3.2 Live Attenuated Vaccine: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
7.5 Capsular Polysaccharide Vaccines
7.5.1 Overview
7.5.2 Capsular Polysaccharide Vaccines: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
7.6 Conjugate Vaccine
7.6.1 Overview
7.6.2 Conjugate Vaccine: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (US$ Million)

8. Typhoid Fever Vaccines Market Analysis - by Route of Administration
8.1 Overview
8.2 Typhoid Fever Vaccines Market Revenue Share, by Route of Administration (2019 and 2027)
8.2.1 Oral
8.2.1.1 Overview
8.2.2 Oral: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (US$ Million)

9. Typhoid Fever Vaccines Market Revenue and Forecasts to 2027 - Geographical Analysis
9.1 North America: Typhoid Fever Vaccines Market
9.1.1 Overview
9.1.2 North America: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (USD Million)
9.1.3 North America: Typhoid Fever Vaccines Market, by Vaccine Type, 2018-2027 (USD Million)
9.1.4 North America: Typhoid Fever Vaccines Market, by Route of Administration, 2018-2027 (USD Million)
9.1.5 North America: Typhoid Fever Vaccines Market, by Country, 2019 & 2027 (%)
9.1.6 US: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (USD Million)
9.1.6.1 US: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (USD Million)
9.1.6.2 US: Typhoid Fever Vaccines Market, by Vaccine Type, 2018-2027 (USD Million)
9.1.6.3 US: Typhoid Fever Vaccines Market, by Route of Administration 2018-2027 (USD Million)
9.1.7 Canada: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.1 Canada: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.2 Canada: Typhoid Fever Vaccines Market, by Vaccine Type, 2018-2027 (USD Million)
9.1.7.3 Canada: Typhoid Fever Vaccines Market, by Route of Administration 2018-2027 (USD Million)
9.1.8 Mexico: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.1 Mexico: Typhoid Fever Vaccines Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.2 Mexico: Typhoid Fever Vaccines Market, by Vaccine Type, 2018-2027 (USD Million)
9.1.8.3 Mexico: Typhoid Fever Vaccines Market, by Route of Administration 2018-2027 (USD Million)

10. Impact of COVID-19 Pandemic on Global Typhoid Fever Vaccines Market
10.1 North America: Impact Assessment of COVID-19 Pandemic

11. Company Profiles
11.1 Paxvax Inc.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 PT Bio Farma
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 BIO-MED
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Sanofi
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 GlaxoSmithKline plc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments

12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/j1joit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

ADVERTISEMENT
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900